Because most HBV/HIV co-infected patients on combination antiretroviral therapy (cART) have suppressed HBV DNA and normal liver enzymes, the histologic spectrum of liver disease in HBV/HIV coinfection is poorly defined. To address this gap in knowledge, we conducted a prospective study to comprehensively characterize liver disease severity assessed by liver biopsy in a well-defined cohort of HBV/HIV patients in North America receiving cART.
INTRODUCTION
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infect 257 million and 42 million persons worldwide, respectively (1) . Due to shared routes of transmission, coinfection with HBV and HIV is common. Cohorts of HIV-infected individuals assembled in Europe and the US have noted HBV coinfection in 5-15% (2-7), and antibody to HIV is associated with a 25-fold increase HBV coinfection (8) . Initially, the morbidity and mortality associated with HIV infection far exceeded the complications of HBV infection. However, with major advances in combination antiretroviral therapy (cART), liver-related mortality has supplanted acquired immunodeficiency syndrome (AIDS)-related mortality as a major complication in HBV-HIV coinfection (9) . Despite the widespread use of antiviral agents active against both HBV and HIV, liver-related mortality remains the second leading cause of death among coinfected patients (6, 9) . Current HIV treatment guidelines from the Department of Health and Human Services recommend that all persons with HBV-HIV coinfection should be treated with cART containing tenofovir (TF) plus lamivudine (3TC) or emtricitabine (FTC) (2) (3) (4) 10, 11) . Despite the well-established guidelines on antiviral regimens in the management of individuals with HBV-HIV coinfection (2) (3) (4) 10, 11) , there are limited prospective data on the extent of HBV control (12) . Furthermore, because liver biopsy is rarely performed in HBV-HIV patients, the histologic spectrum of disease severity in the era of TF-containing cART is unknown. To address this knowledge gap, the HBV-HIV Cohort, an NIHfunded ancillary study of the Hepatitis B Research Network (HBRN) (13) was developed. The main aim of this multicenter cohort study was to assess the histologic spectrum of liver disease and its clinical and virologic correlates in a well-defined, geographically diverse cohort of HBV-HIV patients in North America. The aim of this report is to describe, in cross-sectional nature, the baseline data from this cohort.
PATIENTS AND METHODS
Adult patients with HIV/HBV were recruited from 8 HBRN sites in the US and Canada (Virginia Commonwealth University, University of California, San Francisco, University of Texas, Southwestern, Johns Hopkins University, University Health Network, Toronto, Washington University Saint Louis, Massachusetts General Hospital, NIDDK, National Institute of Health) to participate in this prospective observational study. Inclusion and exclusion criteria for the study are listed in the Appendix. All included subjects were anti-HIV positive and hepatitis B surface antigen positive (HBsAg) for at least 6 months. Those with hepatitis C virus (HCV) RNA, decompensated cirrhosis, or hepatocellular carcinoma (HCC) were excluded. Study participants agreed to undergo liver biopsy at study entry regardless of clinical or laboratory tests as long as they met inclusion/exclusion criteria. By close of enrollment 139 participants attended a research assessment, 120 of whom had a liver biopsy (Fig. 1 ). Of these, 114 subjects had a liver biopsy within 12 months of enrollment with central reading, which was required for this report. The institutional review board at each center approved the protocol, and participants gave written informed consent. The study is registered at ClinicalTrials.gov (NCT01924455).
Standardized research assessments were conducted by study personnel (clinical research investigators and their research staff) based on a common research protocol operations manual.
Demographic data
Data on demographics (age, gender, race/ethnicity, continent of birth, education) and health behaviors (e.g., alcohol use, risk factors for HIV, and HBV) were self-reported at the time of enrollment. Duration of HIV and/or HBV as well as current and past cART use was collected but was unable to be verified in many subjects due to the fragmented care received from different health providers at various sites between diagnosis and enrollment. Alcohol use was assessed with the alcohol use disorder identification test (AUDIT). Increased-risk was defined as an AUDIT score of 8-15, high-risk as a score $16 (14) . Clinical assessment included waist circumference, height and weight, utilized to calculated body mass index (BMI), presence of diabetes mellitus (DM), and evidence of lipodystrophy (mild, moderate or severe) (15) .
Laboratory data
Laboratory testing by local site included hematology, basic metabolic, hepatic panel including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), phosphate, platelet count, and CD4/CD8. Normal ALT was defined as #30 U/L in men and ,20 U/L in women (16) . Laboratory data were collected within 12 weeks of liver biopsy in all but 10 subjects in whom liver biopsy was performed 13-38 weeks prior to enrollment.
HIV stage (1-4) was defined by CD4 count at entry ($500, 350-499, 200-349, and ,200 cells/mm 3 , respectively) according to 2005 World Health Organization Guidelines (17) . Data were entered by study coordinators or the central lab and transmitted the HBRN Data Coordinating Center (DCC, University of Pittsburgh).
Virologic data
Results of local viral testing (HBsAg, HBV e antigen/antibody, HBV DNA, HCV antibody, HIV RNA, hepatitis delta antibody) were recorded. Serum was collected for central testing, stored at the NIDDK biorepository and sent to the HBRN Central Laboratory (University of Washington) for quantitative HBsAg (qHBsAg) and quantitative hepatitis e antigen (qHBeAg), HBV DNA and genotype, and HBV precore/basal core promoter (PC/BCP) mutations (Roche, Branchburg, NJ).
Histologic data
Liver biopsy was performed in the standard fashion. Unstained slides were submitted for H&E and Masson trichrome staining by a central lab. Histological findings were scored blindly with respect to clinical data, including HIV status by the HBRN Pathology Committee (DEK, chair). Total length of biopsy was recorded. While the number of portal tracts was not recorded, each biopsy was assessed as adequate or inadequate by the central pathology committee with a minimum of three portal tracts required to be adequate. The primary outcomes for this report are necroinflammatory activity assessed by the Ishak Histologic Activity Index (HAI), and fibrosis assessed by the Ishak fibrosis score (18) . The HAI is a global scale of hepatic inflammation calculated as the sum of lobular, periportal, portal inflammation, and confluent necrosis scores, with a possible range 0-18. The Ishak fibrosis score ranges from 0-6 and we have defined stage 2 and above as significant fibrosis, and stage 3 and above as advanced fibrosis. Steatosis/steatohepatitis was graded by methods similar to those used in the HALT-C trial (19) . Specifically, Figure 1 . Flow of patients from screening to enrollment steatosis was graded by the proportion of hepatocytes showing steatosis at low magnification (None, ,5%, 5-33%, 34-66%, and .66%), and steatohepatitis was based on the presence of a distinctive pattern of injury (characteristic hepatocyte ballooning with or without Mallory-Denk bodies and perisinusoidal fibrosis).
Statistical analysis
Descriptive statistics summarize demographic, clinical, and virologic characteristics of participants at study entry (N 5 139), as well as these characteristics and histologic characteristics of participants with liver biopsy within 12 months of enrollment (N 5 114). Frequencies and percentages are reported for categorical data. Depending on the distribution of the data, either means and standard deviations, or medians and interquartile range (IQR), are reported for continuous data.
The primary aim of this cross-sectional analysis was to describe the histologic spectrum of liver disease (inflammation and fibrosis) at study entry. Linear regression models were used to test and estimate associations between demographic, clinical, serologic, and virologic characteristic and HAI (dependent variable). The following characteristics were first investigated in simple linear regression models: age, sex, race/ethnicity, tobacco use, marijuana use, coffee (cups per day), tea (cups per day), alcohol use, BMI, history of diabetes, ALT, AST, AST/ALT ratio, platelets, AST to platelet ratio index (APRI) (20) , FIB-4 index (21), HIV stage (0-3), lipodystrophy/lipoatrophy grade (0-3), undetectable HIV RNA (,20 copies/mL), CD4, CD4%, CD8, CD8%, HBV duration, HBeAg positive, qHBeAg level, undetectable HBV DNA (,20 IU/ mL), suppressed HBV DNA (,1000 IU/mL), HBV DNA incomplete suppression (defined as HBV DNA $1000 IU/mL and HIV RNA ,20 copies/mL), HBV DNA level, and qHBsAg level. Due to low representation, Asian ethnicity/ race was collapsed with the "other" category. Likewise, due to low representation, high-risk alcohol use was collapsed with increased-risk at "at-risk alcohol use." Since qHBeAg levels and qHBsAg were skewed, they were log-transformed (natural log for qHBeAg, 10-base for qHBsAg) to reduce the impact of skewness. Factors that were associated at p , 0.20 were then entered into a multivariable regression model to identify factors independently associated with inflammation; variables that had p , 0.10 were removed using a step-wise variable selection method. Quantitative HBeAg level was not considered for multivariable models as it was only available for a subgroup of HBeAg positive patients. Given the high correlation between ALT and AST, the AST/ALT ratio was considered. In addition, separate models evaluated each with the additional independent variables that met the multivariable model criteria. Results are reported as regression coefficients and corresponding 95% confidence intervals. This methodology was repeated using logistic regression to evaluate associations with the binary outcome of advanced fibrosis. Finally, models starting with APRI and FIB-4, respectively, were constructed to determine associations with advanced fibrosis, independent of these biomarkers. Separate models evaluated each with additional independent variables that met the multivariable model criteria, but were not used to calculate these measures (e.g., ALT and platelet for APRI). The results are reported as odds ratios and 95% confidence interval and p-values.
Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). All reported p -values are two-sided; p-values ,0.05 are considered to be statistically significant.
RESULTS

Characteristics of the cohort
Among the enrolling sites, 351 patients were screened, of which 139 were consented. The most common reasons for not participating were refused/no consent (n 5 129), refused liver biopsy (n 5 66), hepatic decompensation (n 5 9), and liver cancer (n 5 4) (Fig. 1) . Of those enrolled, 19 did not undergo biopsy due to logistical (transportation and scheduling conflicts) or financial reasons. Six subjects underwent liver biopsy either more than 365 days prior (n 5 5) or after (n 5 1) enrollment, leaving 114 subjects with histology data. Liver biopsies were performed a median (IQR) of 21 days (0-47) from the date of the enrollment research assessment. Table 1 shows the major demographic and clinical features of the enrolled participants and the histology analysis sample. Among enrolled participants, the mean (SD) age was 49 (8.8), 92% were male, 32% were non-Hispanic white, and 51% were non-Hispanic Black. Most (84%) had had at least a high school education, 64% were never married, and 65% were not working. Increased risk alcohol use was observed in 7%; no participants had high-risk use. Only 12 (9%) reported history of having diabetes. The presumed primary mode of HIV and HBV infection was sexual transmission (accounting for $92% of both infections), with 91% of such transmission among men having sex with men (MSM). The median (IQR) duration of co-infection was 14 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) years. Most participants had stage 1 (68%) or 2 (16%) HIV disease and 11 (9%) had CD4 ,200 cells/mm 3 . Almost all participants (99%) used cART which included anti-HBV coverage as part of cART in 91% with either tenofovir with or without FTC or 3TC (78%) or entecavir (14%). Lipodystrophy was observed in 16%. Table 2 shows the laboratory and serologic results. Among enrolled participants, median (IQR) ALT was 28 (19-41) U/L with 53% having a normal ALT. Median (IQR) AST was 29 (23-40) U/L and ALP was 84 (68-106) U/L. The median (IQR) platelet count was 200,000 (174-236,000) mm 3 . The median (IQR) APRI and FIB-4 scores were 0.34 (026-0.57) and 1.34 (0.99-1.86), respectively. HIV RNA was below detection (,20 copies/mL) in 75%. In those with detectable HIV RNA, proportion with levels 20-100, 100-10,000, and .10,000 copies/ml were 32%, 39%, and 23%, respectively. The median (IQR) CD4 count was 568 cells/mm 3 (337-713). Only 1 patient was anti-HDV positive. HBeAg was positive in 62%, and 57% had undetectable HBV DNA (,20 IU/mL) while 80% were suppressed (HBV DNA ,1000 IU/mL). Median (IQR) HBV DNA in those with detectable DNA was 933 (62-28272) IU/mL. Incomplete HBV suppression ($1000 IU/mL) in the setting of HIV RNA suppression (,20 copies/mL) was observed in 7%. In the 97 subjects with quantifiable HBsAg, median (IQR) serum qHBsAg level was 1478 (381, 10111) IU/mL and in 65 HBeAg positive participants with detectable levels, median (IQR) qHBeAg level was 14.6 (1.8, 273.2) IU/mL. The frequency of basal core promotor (BCP) mutations A1762T and G1764A alone or in combination in those with detectable HBV DNA (n 5 18) were 16%, 16%, and 16%, respectively while the frequency of G1896A was seen on only 6% and no patients had the G1899A mutation. Antidelta antibody was only positive in 1 participant. Results are similar for the histology analysis sample (Table 2) .
Histologic spectrum of disease
Most (99%) of liver biopsies were deemed adequate for histologic assessment by the HBRN central pathology committee. Liver biopsies were .10 mm in length in 93% of the patients and .15 mm in 72%. Figure 2 shows the proportion of participants with each grade of inflammation (0-4) by type (portal, lobular, periportal). Confluent necrosis was rare, observed in only 6 (5%) participants with one case showing multiacinar necrosis (score 6). The median (IQR) HAI was 3 (2-4). Most participants (88%) had minimal to mild inflammatory activity (total inflammation score #5). There was at least mild to moderate periportal, lobular, and portal inflammation (scores $2) in 14%, 31%, and 22% of participants, respectively. Among those with a biopsy, 36.9% had significant fibrosis (Ishak 2-6) and 23.7% had advanced fibrosis (Ishak 3-6) with only 4 patients (5%) showing cirrhosis (Ishak 5-6), Fig. 3 . Over a quarter (29.0%) had .5% steatosis and 10% had NASH (8% definite and 2% probable). Of the 7 subjects (6.4%) with at-risk alcohol use 4 had ,5% steatosis and 3 had grade 1 (5-33%) steatosis while none had steatohepatitis. The spectrum of disease (i.e., HAI and advanced fibrosis) did not vary by clinical site (p 5 0.88 for HAI with F-test, and p 5 0.21 with exact chi-square test).
Factors associated with inflammation and fibrosis Table 3 shows the unadjusted and adjusted associations between demographic, clinical, and serologic characteristics with HAI. On univariate analysis, having a history of diabetes, higher ALT (continuous) or having an ALT above the upper limit of normal (ULN), higher AST, lower platelets, lower CD4%, detectable HIV RNA, and detectable HBV DNA (.20 IU/mL) were significantly (p values for all ,0.05) associated with hepatic inflammation. After adjusting for other factors, platelets, CD4%, detectable HIV RNA and detectable HBV DNA were no longer significantly associated with HAI, whereas a history of diabetes (p 5 0.002) and AST (p , 0.001) were. Participants with history of diabetes had on average a higher HAI (by 2.1 points) than those without any history of diabetes (95% CI, 0.8-3.4), and each 10 unit higher AST was associated with a 0.5 point higher HAI (95% CI, 0.3-0.7). In addition, tobacco use was independently associated with inflammation (p 5 0.02), such that current tobacco users had on average a 1.0 point higher HAI score than never users (95% CI, 0.1-2.0). When AST was replaced by ALT in the multivariable model, the estimate (95% CI) for ALT was 0.28 (95% CI, 0.1-0.4) per 10 IU/L; p , 0.001. Sex, age, race/ethnicity, BMI, marijuana use, coffee consumption, tea consumption, at-risk alcohol use, AST/ALT ratio, HIV stage, CD4 count, CD8 count, CD8%, lipodystrophy/lipoatrophy grade, HBV duration, HBeAg status, qHBeAg, qHBsAg, suppressed HBV DNA (,1000 IU/mL), and incomplete HBV DNA suppression (HBV DNA $1000 IU/mL and HIV RNA ,20 copies/mL) were not significantly associated with HAI in univariate or multivariable analysis. Table 4 shows unadjusted and adjusted associations between demographic, clinical, and serologic characteristics with advanced fibrosis. On univariate analysis, non-Hispanic black race, higher ALT, higher AST, lower platelets, higher APRI and FIB-4 were significantly associated with advanced fibrosis (p , 0.05). On multivariable analysis, race/ethnicity was no longer significantly associated with advanced fibrosis, whereas ALT (p 5 0.03) and platelets (p 5 0.02) were. Each 10 unit higher ALT was independently associated with 19% greater odds of advanced fibrosis (OR 1.19 per 10 U/L; 95% CI 1.01-1.41), and for each 20,000 mm 3 higher platelets, the odds of advanced fibrosis were 19% lower (OR 0.81 per 20000 mm 3 ; 95% CI, 0.67-0.97). In alternative models starting with either APRI or FIB-4, no other variables were independently related to advanced fibrosis. After adjusting for other variables, HBV DNA stratum (undetectable, detectable but ,1000 IU/mL, or $1000 IU/mL at any level) was not associated with hepatic fibrosis.
DISCUSSION
Coinfection of HBV with HIV has been associated with a markedly increased risk of liver-related mortality compared to HIV infection alone (22) . HIV treatment guidelines recommend that all HIV-infected persons with active HBV infection (HBsAg1) undergo treatment of both infections with cART including tenofovir (2-4,10,11). However, the impact of these potent, dually active antiviral regimens on HBV-related liver disease is incompletely understood because liver biopsy is rarely performed in HBV-HIV patients (12) . In this context, our data provides novel and clinically important findings regarding the spectrum of liver disease in persons living with HIV-HBV coinfection.
In our cohort, the magnitude of liver inflammation was mild, consistent with suppressed HBV replication. Importantly however, the degree of hepatic fibrosis was unexpectedly high with over a third (37%) of participants with significant fibrosis (Ishak 2-6) and 24% with advanced fibrosis (i.e., bridging fibrosis or cirrhosis) despite the majority having suppressed HIV and HBV at the time of biopsy. This finding compares to the 2003 report from Lacombe and colleagues who reported histologic findings on 104 HBV-HIV patients and found F2-4 fibrosis in 67% (23) . A separate study from France in 59 HBV-HIV patients (33 of whom were on 3TC or FTC combined with TDF), found that 40% had inflammation (A1-A3), 34% with advanced fibrosis, and 10% had .10% steatosis (24) . However, our findings were similar to a more recent study using vibration controlled transient elastrography in a cohort of 92 HIV-HBV subjects on cART (12) . The slightly lower proportion of advanced fibrosis in our cohort may reflect differences in demographics, duration of infection, duration of anti-HBV therapy, and/or duration of HBV prior to cART containing TDF. Multivariate analysis revealed that higher levels of liver enzymes (AST or ALT) and lower platelets were associated with advanced fibrosis and are likely to reflect ongoing low level inflammatory activity, possibly related to low level intrahepatic HBV replication and transcription. Similarly, higher APRI and FIB-4 reflected the presence of advanced fibrosis. However, our observation that few patients had high APRI or FIB-4 most likely reflects the high proportion with normal ALT due to HBV suppression with cART. The observation of more advanced fibrosis also raises the possibility that HIV coinfection itself alters the intrahepatic milieu to promote fibrogenesis, as has been described for other forms of liver disease (25) (26) (27) (28) . These include increases in TGF-b production and signaling, increased oxidative stress, and increased hepatocyte apoptosis (26) . Concurrent liver diseases, such as hepatic steatosis and steatohepatitis, may also have a role in the pathogenesis of fibrosis in patients with HIV/HBV coinfection. We found that nearly 30% of participants had evidence of steatosis involving more than 5% of hepatocytes and 10% had histologic features of steatohepatitis. To further explore the factors associated with steatosis and elevated liver enzymes despite HBV suppression in our cohort, additional testing for insulin resistance and dyslipidemia by a central laboratory are planned. However, our findings suggest that non-alcoholic fatty liver disease may contribute to liver disease in HIV-infected patients similar to those with HBV mono-infection (29) . Although selfreported past-year at-risk alcohol use was uncommon and not related to hepatic inflammation or advanced fibrosis in our sample, may have been underreported or not reflective of longerterm alcohol use. Thus, alcohol use may also play a role. Taken together, these findings underscore the silent, potentially insidious nature of HBV related liver disease in HIV infected persons, even those with ostensible viral control. Our data suggest that enhanced vigilance to exclude advanced fibrosis should be performed in all persons with HBV and HIV coinfection.
We observed that incomplete HBV suppression was associated with liver inflammation and, if fibrogenesis is driven by incomplete control of HBV infection, the addition of other antiviral drugs may be indicated for persons with incomplete HBV suppression. However, it is uncertain that the addition of entecavir to tenofovir would be effective since most HIV-infected patients are treated with tenofovir in combination with lamivudine or emtricitabine which, like entecavir, are nucleoside(tide)s that target HBV polymerase. Data is also needed on the role of tenofovir alafenamide (TAF) since participants in this cohort were largely treated with TDF. Interestingly, in studies directly comparing these two forms of tenofovir, patients treated with TAF were more likely to normalize serum ALT levels (30, 31) . While modifications or intensification of nucleos(t)ide analog treatment warrants further study in this population, our findings highlight the need for novel agents and approaches to control HBV infection, including those that lead to functional cures (e.g., anti-HBs seroconversion).
Prior to effective cART, Colin and colleagues compared HBV DNA and liver histology in 67 anti-HIV negative HBV1 patients with 65 HBV-HIV co-infected patients and found that coinfected patients had lower ALT (103 vs. 188 U/L; p 5 0.0001), higher HBV DNA (p 5 0.01), and were more likely to have cirrhosis (28% vs. 13%; p 5 0.04) despite similar inflammation scores (32) . In contrast to the study by Colin (32), our cohort included patients on established cART. More recently, Lacombe and colleagues identified HBV genotype G (OR 12.6), use of efavirenz (OR 3.55), and HIV duration .9.5 years (OR 3.86) as independent predictors of significant fibrosis; use of "anti-HBV drugs" (3TC, TDF, or interferon) was not related (23) . Associations with HBV DNA or HBV e antigen/antibody were not evaluated. Because most of our cohort had suppressed HBV DNA, we were not able to confirm the association of HBV genotype with fibrosis. A later report from the same French group of 134 HBV-HIV co-infected patients found HCV and HDV coinfections, but not use of 3TC or TDF, to be associated with advanced fibrosis (33) . We excluded those with active HCV and did not have enough participants with HDV to evaluate associations with this co-infections.
These studies highlight the limited data on the histologic spectrum of liver disease in HBV-HIV patients treated with longterm TDF (34, 35) and lack of data from North America, especially in the era of cART (36, 37) . One study from France suggested that HBV viremia was undetectable in the majority (71% of 205) on cART (30) while a more recent studies from the Netherlands (38) and Spain (12) showed 92 and 89% had undetectable HBV DNA after several years of cART containing anti-HBV therapy. In our study, 56% had detectable HBV DNA while HIV RNA was below detection (local laboratory) in 75%. In those with detectable HIV RNA, proportion with levels .10,000 copies/ml was 23%, suggesting that non-compliance with cART is only partially responsible for incomplete HBV suppression. In a longitudinal study of 165 coinfected patients starting cART, HBV DNA was detected in 21% of subjects despite reporting .95% adherence (39) . To address the role of cART compliance on HBV suppression, we identified 7% as having incomplete suppression based on our predefined criteria of an undetectable HIV RNA in the setting of a detectable HBV DNA .1000 IU/L. Interestingly, after adjusting for other variables, HBV DNA stratum (undetectable, detectable but ,1000 IU/mL, or $1000 IU/mL at any level) was not associated with hepatic fibrosis. Prior studies of HBV mutations in untreated HBV-HIV patients identified similar BCP mutations A1762T and G1764A compared to HBV monoinfected patients when adjusted for HBV genotype (40) . Although we did not analyze BCP mutations by HBV genotype, the prevalence of these mutations were similar in our cohort of treated patients with detectable HBV DNA suggesting other factors associated with incomplete suppression. HBV deep sequencing analysis is underway to help elucidate viral resistant mutations to tenofovir in these patients. The strengths of our study are the sample size and the central reading of liver biopsies by the HBRN pathology committee. Conversely, potential limitations of our study include the cross-sectional design and the self-selection of patients who were willing to undergo liver biopsy who therefore may not reflect all of adults with HBV-HIV coinfection. In addition, similar to other studies (12), we do not have baseline data prior to cART and could not account for duration of infections, nadir CD4 counts, impact or duration of anti-HBV therapy alone or as part of prior cART, or timing of prior HBeAg seroconversion as many patients received care by other providers at other sites prior to enrollment. Incomplete data on cART exposure on all patients, use of older HIV medications (such as nucleoside reverse transciptase inhibitors) or HIV itself that might have accelerate liver disease, and changes in cART exposure over time may have impacted the natural history of HBV. Furthermore, the time from liver biopsy and baseline data collection may have been up to 52 weeks. However, in our experience, laboratory tests and liver histology do not significantly change over that interval. As with any liver biopsy study, there may have been sampling error. Lastly, we were not able to compare liver histology in our HBV/HIV cohort to those with HBV alone on tenofovir to determine if those with HBV/ HIV have worse liver disease outcomes. Notwithstanding these limitations, our study remains one of the largest on liver histology in this understudied population.
In summary, in this North American cohort of HBV-HIV coinfected subjects on dually active cART, a comprehensive histologic evaluation reveals that one third have significant fibrosis with low rates of cirrhosis despite low liver enzymes and HBV viral suppression with excellent control of both infections. Additional analyses of this cohort are underway to better define histologic progression and/or regression associated with cART that includes tenofovir (41) by paired liver biopsy to determine if factors other than HBV suppression, such as specific components of cART, identify predictors of steatosis and to determine noninvasive assessments to predict which patients might need to undergo liver biopsy to identify significant fibrosis. Until then, HBV-HIV patients require close monitoring for disease severity.
